Background: Influenza has been an acknowledged cause of respiratory disease for decades. However, considerable related, and often unappreciated, disease burden stems from cardiovascular complications, exacerbations of underlying medical conditions and secondary respiratory complications, with the highest burden in the elderly. This novel study combines the gold standard method of a randomized controlled trial with real-world data collection through national registries, to assess the relative effectiveness of high-dose (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD) in preventing cardio-respiratory hospitalizations in a large cohort of adults aged ≥65 years.
Methods And Results: This trial (NCT04137887) is a Phase III/IV, modified double-blinded, randomized, registry-based trial, conducted by the Finnish Institute for Health and Welfare (THL). Participants (n>120 000) are being enrolled over multiple influenza seasons and randomized (1:1) to receive QIV-HD or QIV-SD. Participant follow-up is based on data collection up to 11 months post-vaccination using Finnish national health registries. The primary objective is to demonstrate the relative superior effectiveness of QIV-HD over QIV-SD in preventing cardio-respiratory hospitalizations up to 6 months post-vaccination. Safety will be assessed using automated online tools throughout the study, with causality assessed using statistical and probabilistic methods; serious adverse reactions and adverse events of special interest will be investigated individually.
Conclusion: This large, real-world, randomized study will provide valuable insight into the contribution of influenza in causing severe cardio-respiratory events, and the role of vaccination with QIV-HD in reducing these outcomes compared to the current standard of care.
Funding: Sanofi Pasteur.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2021.03.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination.
China CDC Wkly
December 2024
Department of Biostatistics, School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Introduction: The cost-effectiveness of vaccination strategies plays a crucial role in managing infectious diseases such as influenza within public health systems. This study evaluated the cost-effectiveness of vaccination compliance strategies by comparing an "adherence" strategy, which promoted continuous vaccination uptake, with a "volunteer" strategy through model-based simulations.
Methods: We developed a novel hybrid model that integrates continuous-time agent-based models (ABMs) with a Markov model to simulate vaccination behaviors and disease dynamics at the individual level.
Clinical advancements in mRNA vaccines against viral infections.
Clin Immunol
December 2024
Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:
Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.
View Article and Find Full Text PDFRe: 'The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France' by Bricout et al.
Clin Microbiol Infect
December 2024
Scientific Committee of the Foundation 'Allineare Sanità e Salute' Milan, Via Ricordi, 4 - 20131 Milano - Italy. Electronic address:
Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
Vaccine
December 2024
Division of Infectious Diseases, Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. Electronic address:
Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.
Sci Rep
December 2024
State Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!